Tailored second-line therapy in asthmatic children with the Arg(16) genotype.

The Arg(16) β(2) receptor genotype confers increased susceptibility to exacerbations in asthmatic children taking regular LABA (long-acting β(2) agonists). We therefore evaluated using montelukast as an alternative to salmeterol as tailored second-line asthma controller therapy in children expressing this susceptible genotype. A total of 62 persistent asthmatic children with the homozygous Arg16 genotype were randomized to receive salmeterol (50 μg, b.i.d.) or montelukast (5 or 10 mg, once daily) as an add-on to inhaled fluticasone for 1 year. School absences (the primary outcome) were reduced with montelukast compared with salmeterol {difference in score=-0.40 [95% CI (confidence interval), -0.22 to -0.58]; P=0.005}. Salbutamol use was also reduced with montelukast compared with salmeterol [difference in score=-0.47 (95% CI, -0.16 to -0.79); P<0.0001]. Greater improvements occurred in both symptom and quality of life scores with montelukast against salmeterol, whereas there was no difference in FEV(1) (forced expiratory volume in 1 s). In conclusion, montelukast may be suitable as tailored second-line controller therapy instead of salmeterol in asthmatic children expressing the susceptible Arg(16) genotype, a move towards a personalized medicine approach to management.

[1]  Martyn R Partridge,et al.  British Guideline on the Management of Asthma , 2008, Thorax.

[2]  I. Hall,et al.  The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. , 2003, British journal of clinical pharmacology.

[3]  Yu Qin,et al.  Effect of β2 -adrenergic receptor gene Arg16Gly polymorphisms on response to long-acting β2-agonist in Chinese Han asthmatic patients , 2014, Multidisciplinary Respiratory Medicine.

[4]  B. Lipworth,et al.  Effects of treatment with formoterol on bronchoprotection against methacholine. , 1998, The American journal of medicine.

[5]  I. Hall,et al.  Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. , 1998, The European respiratory journal.

[6]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Erickson,et al.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.

[8]  U. Grouven,et al.  Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review , 2008, Thorax.

[9]  I. Sayers,et al.  β2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study , 2006, The Lancet.

[10]  S. Weiss,et al.  The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. , 2002, American journal of respiratory and critical care medicine.

[11]  G. Guyatt,et al.  Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. , 1997, The European respiratory journal.

[12]  B. Lipworth,et al.  Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol , 2006, Thorax.

[13]  E. Bleecker,et al.  Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. , 2010, American journal of respiratory and critical care medicine.

[14]  E. Bateman,et al.  Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. , 2011, The Journal of allergy and clinical immunology.

[15]  B. Lipworth,et al.  Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. , 2003, American journal of respiratory and critical care medicine.

[16]  S. Liggett.  The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. , 2000, The Journal of allergy and clinical immunology.

[17]  J. Kramer,et al.  Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. , 2009, The New England journal of medicine.

[18]  E. R. Sutherland,et al.  Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial , 2009, The Lancet.

[19]  B. Lipworth,et al.  Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. , 2001, Chest.

[20]  B. Lipworth,et al.  Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. , 2009, The Journal of allergy and clinical immunology.

[21]  Daniel J Jackson,et al.  Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. , 2010, The New England journal of medicine.